Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Disrupting two cell mechanisms in combination can suppress aggressive breast cancer in mice

30.09.2003


Targeting angiogenesis alone not effective



Scientists at Memorial Sloan-Kettering Cancer Center and colleagues found that by inhibiting both the proteins responsible for breast cancer growth and those required for the formation of new blood vessels, they could more effectively suppress the growth of extremely aggressive breast tumors in mice. In a surprising finding, the researchers showed that mice harboring a mutation commonly found in human breast cancers developed tumors that were able to grow despite a defect in angiogenesis or new blood vessel formation. However, when these mice were also treated with a chemotherapy drug under development at Memorial Sloan-Kettering that inhibits Hsp90 (a cell survival protein), the chemotherapy was significantly more effective in the mice with abnormal angiogenesis so that tumor growth was completely suppressed. These findings, published in the October 3 issue of the Proceedings of the National Academy of Science, suggest that combining agents that target these two cellular functions should be evaluated for the treatment of advanced breast cancer.

"It was unexpected that the tumors would be able to overcome an inhibition to angiogenesis," said Paola de Candia, Ph.D., a researcher in the Benezra laboratory and first author of the study. "The mice developed large tumors despite the impairment in their ability to form new blood vessels caused by Id deficiency. The tumors were morphologically different with cystic (liquid) centers and a narrow rim of tumor cells. The cells in the rim continued to proliferate and invade tissue. Ultimately, they metastasized, suggesting that inhibiting tumor angiogenesis was not sufficient to suppress tumor growth and progression."


In earlier research, the study’s senior author, Dr. Robert Benezra, and colleagues had shown that mice with two of their four Id proteins genetically altered or "knocked out" had impaired angiogenesis which resulted in an inability to grow capillaries from existing blood vessels. When tumors were transplanted in these Id deficient mice, growth was either slowed or the tumors regressed.

For this study, transgenic mice were used that express the HER2/neu activated oncogene, a mouse model of breast cancer that is much more similar to human disease than transplanted tumors. This genetic modification leads to the development of aggressive breast tumors in 100 per cent of the cases. These mice were then crossed with mice that were Id deficient. The Id deficient, HER2/neu mice with abnormal angiogenesis developed breast tumors at the same rate as those with normal Id genes suggesting that Id deficiency and abnormal angiogenesis could not retard the growth of these HER2/neu dependent breast tumors. While the impairment in new blood vessel formation did not prevent tumor growth, the appearance of the tumors in the Id deficient mice was very different.

The researchers hypothesized that tumors require stress-induced survival pathways in order to maintain the expression of the neu oncogene and to proliferate. Since the Hsp90 chaperone protein is required to activate these pathways, they tested the effects of the Hsp90 inhibitor 17-AAG on the growth of the tumors. The mice were randomly assigned to 17-AAG treatment or control when the first palpable tumor reached 5 mm. The anti-tumor effect of 17-AAG in the Id deficient mice was dramatic with the tumor growth completely inhibited. This drug was only minimally effective in the mice with normal Id function.

"When mice with aggressive breast cancer were treated with 17-AAG, a drug that inhibits the Hsp90 protein, tumor growth was slowed but not completely suppressed," said David Solit, MD, a principle investigator of the 17-AAG trials and a researcher in the laboratory of Dr. Neal Rosen in the Cell Biology Program at Memorial Sloan-Kettering Cancer Center and co-first author of the study. "However, when 17-AAG was administered to Id deficient mice which are unable to form functional new blood vessels, tumor growth was completely inhibited. The enhancement of the drug’s activity when combined with an anti-angiogenesis model suggests that cells with an impaired vasculature may be more dependent on the Hsp90 chaperone function for survival due to their low nutrient and low pH environment. This provides a rationale for combining anti-angiogenic and Hsp 90 inhibitors in clinical trials for patients with advanced breast cancer."

The findings have implications for the design of future studies combining anti-angiogenic and Hsp90 inhibitor drugs in patients. "Because we have been able to create more sophisticated mouse models that over express the oncogenes found in 25 to 30 per cent of human breast cancer, these models are much more reliable in evaluating drugs," said Robert Benezra, Ph.D., senior author of the study, and head of a laboratory in the Cell Biology Program at Memorial Sloan-Kettering Cancer Center. "The mice are more similar to humans with breast cancer so we are hopeful that our results will be able to translate into clinical trials."


This study’s co-authors include Dr. Neal Rosen, Edi Brogi, Adam B. Olshen and Peter Siegel of Memorial Sloan-Kettering Cancer Center; Dr. Dilip Giri, Lifespan Academic Medical Center at Rhode Island Hospital; and Dr. William J. Muller of MOBIX , McMaster University. It was supported by the American Italian Cancer Foundation and the American Society of Clinical Oncology and by grants from the Breast Cancer Research Foundation and the National Institutes of Health.

Memorial Sloan-Kettering Cancer Center is the world’s oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to www.mskcc.org.

Joanne Nicholas | EurekAlert!
Further information:
http://www.mskcc.org/

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

NASA's Fermi catches gamma-ray flashes from tropical storms

25.04.2017 | Physics and Astronomy

Researchers invent process to make sustainable rubber, plastics

25.04.2017 | Materials Sciences

Transfecting cells gently – the LZH presents a GNOME prototype at the Labvolution 2017

25.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>